Patent ID: 11920130
Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC C

Claim 15:
16. The method of claim 2, wherein the exogenous CAR comprises an antigen-binding domain, a transmembrane domain, a co-stimulatory domain and an intracellular domain, wherein:
the antigen-binding domain is selected from the group consisting of an antibody, an scFv, and a Fab;
the transmembrane domain is selected from the group consisting of an artificial hydrophobic sequence and transmembrane domain of a type I transmembrane protein, an alpha, beta, or zeta chain of a T cell receptor, CD28, CD3 epsilon, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, and CD154;
the co-stimulatory domain is selected from at least one of the group consisting of co-stimulatory domains of proteins in the TNFR superfamily, CD28, 4-1BB (CD137), OX40 (CD134), PD-1, CD7, LIGHT, CD83L, DAP10, DAP12, CD27, CD2, CD5, ICAM-1, LFA-1, Lck, TNFR-I, TNFR-II, Fas, CD30, CD40, ICOS, NKG2C, and B7-H3; and/or
the intracellular domain is selected from the group consisting of cytoplasmic signaling domains of a human CD3 zeta chain, FcyRIII, FcsRI, a cytoplasmic tail of an Fc receptor, an immunoreceptor tyrosine-based activation motif (ITAM) bearing cytoplasmic receptors, TCR zeta, FcRgamma, FcR beta, CD3 gamma, CD3 delta, CD3 epsilon, CD5, CD22, CD79a, CD79b, and CD66d.